Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke[1].
References
[1] Sanz-Cuesta BE, et al. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors. Stroke. 2021 Oct;52(10):3142-3150. DOI:10.1161/STROKEAHA.121.034576
